KAN-001, a Complex Consortium Live Biotherapeutic Product to Augment Cancer Therapy
Time: 11:30 am
day: Conference Day One, Track Two, AM
Details:
- From FMTs to LBPs: A reverse translational approach to creating an optimized and sustainable therapy to augment patients’ immune systems and response to cancer immune checkpoint therapy
- KAN-001 optimization and preclinical testing
- KAN-001 strains in patients: assessing existing KAN-001 strain-level clinical engraftment data de-risks development
